Daewoong's P-CAB Contender Holds Up Well At Phase III
Non-Inferior To Esomeprazole
Executive Summary
South Korean firm presents encouraging Phase III data for its novel P-CAB drug fexuprazan at Digestive Disease Week and hopes the results will accelerate entry into global markets.
You may also be interested in...
Korea’s Home-Grown New Drug Approvals Hit Record High In 2021
South Korea had a milestone year in terms of domestic new drug approvals in 2021, with multiple major pharma firms gaining nods for their in-house developed products, including the country’s first COVID-19 therapeutic, from Celltrion.
Can Daewoong’s P-CAB Unsettle Competition?
Daewoong Pharmaceutical has successfully completed a Phase III clinical trial of next generation gastroesophageal reflux disease (GERD) drug candidate in South Korea, but strong competition awaits from approved P-CAB drugs of CJ Healthcare and Takeda.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.